- Blog
Top Global M&A Deals 2023: Pharmaceutical and Biotechnology Industry
SHARE:
Welcome to the Institute for Mergers, Acquisitions, and Alliances’ overview of the Top Global M&A Deals 2023: Pharmaceutical and Biotechnology Industry. This is your essential guide to the transformative M&A deals in the pharmaceutical sector. From groundbreaking biotech startups to pharmaceutical giants looking to expand their therapeutic portfolios, our monthly report captures the various facets of M&A activities that are advancing this industry.
The pharmaceutical and biotechnology industry is at the epicenter of research and development. This has led to an increase in the pharmaceutical industry’s M&A deals, consolidating expertise, resources, and technological capabilities. These strategic moves enable companies to share knowledge, diversify their product ranges, and scale their operations in the highly competitive market.
Pharma is multi-disciplinary by nature. It involves the intricate blending of chemical, biological, and data sciences to develop new therapies, diagnostics, and vaccines. Whether it’s the development of cutting-edge gene therapies, targeted cancer treatments, vaccines for emerging infectious diseases, or advancements in personalized medicine, pharma M&A activities serve as a critical tool for driving forward scientific innovation.
As you explore our 2023 report on the biggest pharma mergers, you’ll discover a monthly breakdown of the top deals, offering insights into how the industry is adjusting to scientific advancements, regulatory landscapes, and healthcare needs.
Whether you’re a seasoned industry professional, an investor, or simply curious about the mechanics of the consumer world, our platform delivers a front-row seat to the ongoing evolution of the of the pharmaceutical and biotechnology industry through the lens of M&A.
July
- Deal 1: Reata Pharmaceuticals, Inc. (United States) was acquired by Biogen, Inc. $7.3 billion USD
- Deal 2: CRAFT 1861 Global Holdings Inc. (Canada) was acquired by Nano Cures Inc. (United States) for $2.4 billion USD.
- Deal 3: Versanis Bio, Inc. (United States) was acquired by Eli Lilly and Company (United States) for $1.9 billion USD.
- Deal 4: Quten Research Institute LLC (United States) was acquired by Sanofi (France) for $1.4 billion USD.
- Deal 5: Kerecis, LLC (United States) was acquired by Coloplast A/S (Denmark) for $1.3 billion USD.
August
- Deal 1: Abcam plc (United Kingdom) was acquired by Danaher Corporation (United States) for $6.00 billion USD.
- Deal 2: Celltrion Healthcare Co., Ltd. (South Korea) was acquired by Celltrion, Inc. (South Korea) for $5.34 billion USD.
- Deal 3: Inversago Pharma Inc. (Canada) was acquired by Novo Nordisk A/S (Denmark) for $1.08 billion USD.
- Deal 4: Thorne HealthTech, Inc. (United States) was acquired by L Catterton Partners (United States) for $0.75 billion USD.
- Deal 5: Embark Biotech ApS (Denmark) was acquired by Novo Nordisk A/S (Denmark) for $0.51 billion USD.
September
- Deal 1: Ergomed plc (United Kingdom) was acquired by Permira Advisers Ltd. (United Kingdom) for $0.89 billion USD.
- Deal 2: Intercept Pharmaceuticals, Inc. (United States) was acquired by Alfasigma S.p.A. (Italy) for $0.79 billion USD.
- Deal 3: Glenmark Life Sciences Limited (India) was acquired by Nirma Limited (India) for $0.68 billion USD.
- Deal 4: Zhejiang Langhua Pharmaceutical Co., Ltd (China) was acquired by Viva Biotech (Shanghai) Ltd. (China) for $0.39 billion USD.
- Deal 5: API and CRAMS business of Ind-Swift Laboratories Limited (India) was acquired by Synthimed Labs Private Limited (Synthimed Labs Private Limited—a portfolio company of India Resurgence Fund) (India) for $0.20 billion USD.
October
- Deal 1: Mirati Therapeutics, Inc. (United States) was acquired by Bristol-Myers Squibb Company (United States) for $4.80 billion USD.
- Deal 2: Substantially All of the Over-the-Counter Business of Viatris Inc. (United States) was acquired by Cooper Consumer Health SAS (France) for $2.17 billion USD.
- Deal 3: POINT Biopharma Global Inc. (United States) was acquired by Eli Lilly and Company (United States) for $1.38 billion USD.
- Deal 4: Haleon plc (United Kingdom) was acquired by an undisclosed party for $1.08 billion USD.
- Deal 5: TenX Keane Acquisition (special purpose acquisition company to Form Publicly Listed Citius Oncology) (Cayman Islands) was acquired by Citius Oncology, Inc. (United States) for $0.68 billion USD.
November
- Deal 1: ImmunoGen, Inc. (United States) was acquired by AbbVie Inc. (United States) for $10.10 billion USD.
- Deal 2: Taisho Pharmaceutical Holdings Co., Ltd. (Japan) was acquired by Otemon Co., Ltd. (Japan) for $4.75 billion USD.
- Deal 3: Caraway Therapeutics, Inc. (United States) was acquired by Merck & Co., Inc. (United States) for $0.61 billion USD.
- Deal 4: T3 Pharmaceuticals AG (Switzerland) was acquired by Boehringer Ingelheim International GmbH (Germany) for $0.51 billion USD.
- Deal 5: Bonafide Health, LLC (United States) was acquired by Pharmavite LLC (United States) for $0.43 billion USD.
December
- Deal 1: Karuna Therapeutics, Inc. (United States) was acquired by Bristol-Myers Squibb Company (United States) for $14.00 billion USD.
- Deal 2: Cerevel Therapeutics Holdings, Inc. (United States) was acquired by AbbVie Inc. (United States) for $8.70 billion USD.
- Deal 3: RayzeBio, Inc. (United States) was acquired by Bristol-Myers Squibb Company (United States) for $4.15 billion USD.
- Deal 4: Carmot Therapeutics Inc. (United States) was acquired by Roche Holding AG (Switzerland) for $3.10 billion USD.
- Deal 5: Icosavax, Inc. (United States) was acquired by AstraZeneca PLC (United Kingdom) for $1.10 billion USD.
TAGS:
Stay up to date with M&A news!
Subscribe to our newsletter
